Humanin's impact on pain markers and neuronal viability in diabetic neuropathy model

dc.contributor.authorKelestemur, Muhammed Mirac
dc.contributor.authorBulut, Ferah
dc.contributor.authorBilgin, Batuhan
dc.contributor.authorHekim, Munevver Gizem
dc.contributor.authorAdam, Muhammed
dc.contributor.authorOzcan, Sibel
dc.contributor.authorOzcan, Mete
dc.date.accessioned2026-08-12T17:38:49Z
dc.date.issued2024
dc.departmentFırat Üniversitesi
dc.description.abstractObjective This study investigates the impact of chronic humanin (HN) treatment on pain-related markers (NMDA, substance P, TRPV1, and IL-1 beta) in diabetic mice's dorsal root ganglia (DRG). Additionally, we assess the effects of HN on cellular viability in DRG neurons. Methods In vivo experiments involved 15 days of HN administration (4 mg/kg) to diabetic mice (n = 10). Protein levels of NMDA, IL-1 beta, TRPV1, and substance P were measured in diabetic DRG. In vitro experiments explored HN's impact on apoptosis and cellular viability, focusing on the JAK2/STAT3 pathway. Results Humanin significantly reduced the elevated expression of NMDA, IL-1 beta, TRPV1, and substance P induced by diabetes (p < .05). Furthermore, HN treatment increased cellular viability in DRG neurons through JAK2/STAT3 pathway activation (p < .05). Conclusion These findings highlight the significance of understanding mitochondrial function and pain markers, as well as apoptosis in diabetes. The study provides insights for managing the condition and its complications.
dc.description.sponsorshipTurkish Scientific Technical Research Organization (TUBITAK) [119R084]
dc.description.sponsorshipThis study was supported by Turkish Scientific Technical Research Organization (TUBITAK) under Project No.: 119R084.
dc.identifier.doi10.1080/13813455.2024.2336922
dc.identifier.endpage908
dc.identifier.issn1381-3455
dc.identifier.issn1744-4160
dc.identifier.issue6
dc.identifier.orcid0000-0003-0455-4521
dc.identifier.orcid0000-0002-5080-5160
dc.identifier.orcid0000-0002-3470-1783
dc.identifier.orcid0000-0003-3755-3015
dc.identifier.pmid38599217
dc.identifier.scopus2-s2.0-85189896372
dc.identifier.scopusqualityQ1
dc.identifier.startpage898
dc.identifier.urihttps://doi.org/10.1080/13813455.2024.2336922
dc.identifier.urihttps://hdl.handle.net/11508/58586
dc.identifier.volume130
dc.identifier.wosWOS:001200461300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofArchives of Physiology and Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectHumanin
dc.subjectdorsal root ganglia
dc.subjectpain markers
dc.subjectapoptosis
dc.subjectcell viability
dc.subjectdiabetic neuropathy
dc.titleHumanin's impact on pain markers and neuronal viability in diabetic neuropathy model
dc.typeArticle

Dosyalar